Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock
Thilo Schroeder, insider at PMV Pharmaceuticals
Thilo Schroeder Insider Alerts

Get notified the next time Thilo Schroeder buys or sells PMV Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Thilo Schroeder Insider Information

Director of PMV Pharmaceuticals
Thilo Schroeder, Ph.D. is a Partner at Nextech and has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality.

Thilo is a board member of Revolution Medicines, PMV Pharma, IDEAYA Biosciences (NASDAQ: IDYA), ImaginAb and is a board observer of Black Diamond Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC) and Peloton Therapeutics (acquired by Merck).

Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).

How do I contact Thilo Schroeder?

The corporate mailing address for Mr. Schroeder and other PMV Pharmaceuticals executives is , , . PMV Pharmaceuticals can also be reached via phone at 609-642-6670 and via email at [email protected]

Has Thilo Schroeder been buying or selling shares of PMV Pharmaceuticals?

Over the course of the past ninety days, Thilo Schroeder has sold $374,512.00 in PMV Pharmaceuticals stock. Most recently, Thilo Schroeder sold 800 shares of the business's stock in a transaction on Wednesday, October 6th. The shares were sold at an average price of $30.15, for a transaction totalling $24,120.00.

Who are PMV Pharmaceuticals' active insiders?

PMV Pharmaceuticals' insider roster includes Leila Alland (Insider), Richard Heyman (Director), Winston Kung (CFO), Arnold Levine (Director), David Mack (CEO), and Thilo Schroeder (Director).

Are insiders buying or selling shares of PMV Pharmaceuticals?

During the last twelve months, insiders at the sold shares 61 times. They sold a total of 930,925 shares worth more than $32,658,653.99. The most recent insider tranaction occured on October, 6th when Director Thilo Schroeder sold 800 shares worth more than $24,120.00. Insiders at PMV Pharmaceuticals own 21.8 % of the company.

Information on this page was last updated on 10/6/2021.

Thilo Schroeder Insider Trading History at PMV Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/6/2021Sell800$30.15$24,120.00View SEC Filing Icon  
10/4/2021Sell100$30.08$3,008.00View SEC Filing Icon  
10/1/2021Sell11,541$30.10$347,384.10View SEC Filing Icon  
9/29/2021Sell5,708$30.04$171,468.32View SEC Filing Icon  
9/27/2021Sell1,753$30.11$52,782.83View SEC Filing Icon  
9/17/2021Sell711$30.03$21,351.33View SEC Filing Icon  
9/13/2021Sell13,272$30.20$400,814.40View SEC Filing Icon  
9/9/2021Sell14,329$30.31$434,311.99View SEC Filing Icon  
9/1/2021Sell21,986$30.38$667,934.68View SEC Filing Icon  
8/30/2021Sell13,233$30.05$397,651.65View SEC Filing Icon  
8/27/2021Sell24,442$30.52$745,969.84View SEC Filing Icon  
8/25/2021Sell13,526$31.01$419,441.26View SEC Filing Icon  
8/18/2021Sell26,864$33.34$895,645.76View SEC Filing Icon  
8/16/2021Sell22,183$33.89$751,781.87View SEC Filing Icon  
8/13/2021Sell27,286$34.24$934,272.64View SEC Filing Icon  
8/11/2021Sell34,439$34.04$1,172,303.56View SEC Filing Icon  
8/9/2021Sell22,182$35.53$788,126.46View SEC Filing Icon  
8/6/2021Sell19,900$36.61$728,539.00View SEC Filing Icon  
8/4/2021Sell52,860$35.85$1,895,031.00View SEC Filing Icon  
8/2/2021Sell13,031$34.74$452,696.94View SEC Filing Icon  
7/28/2021Sell8,724$35.76$311,970.24View SEC Filing Icon  
7/26/2021Sell4,839$35.73$172,897.47View SEC Filing Icon  
7/22/2021Sell200$35.61$7,122.00View SEC Filing Icon  
5/28/2021Sell5,100$35.80$182,580.00View SEC Filing Icon  
5/26/2021Sell7,487$35.66$266,986.42View SEC Filing Icon  
5/24/2021Sell22,095$36.03$796,082.85View SEC Filing Icon  
5/10/2021Sell1,787$35.67$63,742.29View SEC Filing Icon  
5/5/2021Sell600$35.64$21,384.00View SEC Filing Icon  
4/12/2021Sell3,903$31.41$122,593.23View SEC Filing Icon  
4/8/2021Sell136,436$34.31$4,681,119.16View SEC Filing Icon  
4/5/2021Sell48,193$33.81$1,629,405.33View SEC Filing Icon  
3/31/2021Sell33,626$32.52$1,093,517.52View SEC Filing Icon  
3/29/2021Sell2,174$32.15$69,894.10View SEC Filing Icon  
3/26/2021Sell35,268$33.44$1,179,361.92View SEC Filing Icon  
3/24/2021Sell34,881$36.50$1,273,156.50View SEC Filing Icon  
See Full Table

Thilo Schroeder Buying and Selling Activity at PMV Pharmaceuticals

This chart shows Thilo Schroeder's buying and selling at PMV Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PMV Pharmaceuticals Company Overview

PMV Pharmaceuticals logo
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Read More

Today's Range

Now: $22.19
Low: $22.10
High: $23.75

50 Day Range

MA: $26.30
Low: $22.19
High: $30.73

2 Week Range

Now: $22.19
Low: $22.09
High: $63.22

Volume

217,123 shs

Average Volume

283,246 shs

Market Capitalization

$1.01 billion

P/E Ratio

14.60

Dividend Yield

N/A

Beta

0.83
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock